Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414403 | 0.91 | MAPT (0.49) | MMEOPRD1OPRM1OPRK1MAPT | |
| SCHEMBL30099581 | 0.90 | FOLH1 (0.45) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29833638 | 0.90 | ECE1 (0.47) | MMESLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL7150981 | 0.90 | MAPT (0.53) | MMESLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL7553789 | 0.90 | MAPT (0.53) | MMESLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL30662551 | 0.90 | CA2 (0.47) | MMEMAPTCA2CA4EPHX2 | |
| SCHEMBL31182817 | 0.89 | OPRD1 (0.46) | MMEOPRD1OPRM1OPRK1MAPT | |
| SCHEMBL30661448 | 0.87 | OPRD1 (0.53) | SLC7A5OPRD1OPRM1OPRK1MAPT | |
| SCHEMBL30661446 | 0.87 | OPRD1 (0.53) | SLC7A5OPRD1OPRM1OPRK1MAPT | |
| SCHEMBL29700057 | 0.87 | MME (0.54) | MMESLC7A5OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | INVO Aesthetics Inc. (US) | 2026-04-23 | — | — | US | claimed |
| US-20240390236-A1 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | TOPIX PHARMACEUTICALS INC (US) | 2024-11-28 | — | — | US | claimed |
| US-12064494-B2 | Methods, compositions, and delivery systems for therapeutic skin treatments | TOPIX PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | claimed |
| US-11433006-B2 | Methods, compositions, and delivery systems for therapeutic skin treatments | TOPIX PHARMACEUTICALS, INC. (US) | 2022-09-06 | — | — | US | claimed |
| US-11376231-B2 | Compositions of bioactive fulvate fractions and uses thereof | OMNI BIOCEUTICAL INNOVATIONS, INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-20220151882-A1 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | TOPIX PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | claimed |
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | INVO Aesthetics Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12370234-B2 | Composition comprising P53-activating peptide | SUPADELIXIR INC. (KR) | 2025-07-29 | — | — | US | disclosed |
| WO-2025084793-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HAND-FOOT SYNDROME OR HAND-FOOT SKIN REACTION | (주) 수파드엘릭사 | 2025-04-24 | — | — | WO | disclosed |
| US-20240390236-A1 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | TOPIX PHARMACEUTICALS INC (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240390236-A1 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | TOPIX PHARMACEUTICALS INC (US) | 2024-11-28 | — | — | US | disclosed |
| US-12064494-B2 | Methods, compositions, and delivery systems for therapeutic skin treatments | TOPIX PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-12064494-B2 | Methods, compositions, and delivery systems for therapeutic skin treatments | TOPIX PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4074303-A2 | COMPOSITION COMPRISING P53-ACTIVATING PEPTIDE | Supadelixir Inc. (KR) | 2022-10-19 | — | — | EP | disclosed |
| US-11433006-B2 | Methods, compositions, and delivery systems for therapeutic skin treatments | TOPIX PHARMACEUTICALS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433006-B2 | Methods, compositions, and delivery systems for therapeutic skin treatments | TOPIX PHARMACEUTICALS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| EP-4046647-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PEPTIDE THAT INHIBITS INTERACTION OF P53 AND FOXO4 | Supadelixir Inc. (KR) | 2022-08-24 | — | — | EP | disclosed |
| US-11376231-B2 | Compositions of bioactive fulvate fractions and uses thereof | OMNI BIOCEUTICAL INNOVATIONS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220151882-A1 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | TOPIX PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220151882-A1 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | TOPIX PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | FGF1, FGF2, HGF | MME 4567/4885SLC7A5 2971/4885OPRD1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.